LAVAL, QC, Aug. 2 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that James Howard-Tripp, Chief Executive Officer of the Company will
present at the 27th Annual Canaccord Adams Global Growth Conference in Boston,
on Thursday, August 9, 2007 at 11:30 a.m. ET.
Interested parties may access the live webcast by visiting the "Events"
section of the homepage of the Company's website at www.labopharm.com. Please
connect at least 15 minutes prior to the presentation to ensure adequate time
for any software download that may be required to join the webcast. An audio
archive of the presentation will be available for 30 days.
The Conference, which is one of the longest running institutional events
focused exclusively on growth companies, will include 270 public and private
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company has a robust
pipeline of follow-on products in both pre-clinical and clinical development.
For more information, please visit www.labopharm.com
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process and the
commercialization of the Company's products thereafter, if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm, Mark A. D'Souza, Chief Financial
Officer, Tel: (450) 686-0207; At The Equicom Group, Jason Hogan, Media and
Investor Relations, Tel: (416) 815-0700, firstname.lastname@example.org; French: Eric
Bouchard, Tel: (514) 844-7997, email@example.com